Clinical Research Training Course

ASTCT Clinical Research Training Course


The American Society for Transplantation and Cellular Therapy is proud to present the Clinical Research Training Course from July 14 - 18, 2021 in Park City, Utah. The program is intended for fellows and junior faculty and will consist of a 5-day in person meeting. Twelve scholars will be selected through a competitive selection process. 


Clinical Research Training Course
Wednesday, July 14 - Sunday, July 18, 2021
Hotel Park City
Park City, UT 

Accepted scholars will arrive to Park City, UT on Tuesday, July 13 as the course will begin promptly on Wednesday morning. Scholars will depart Sunday afternoon. 

Objectives and Curriculum

The course was designed by the ASTCT Board of Directors in 2006 due to the concern that clinical fellowships did not adequately cover the principles of research and how to take findings from the laboratory to the clinic. The Clinical Research Training Course will help fellows and junior faculty close the gap by addressing these concerns through formal presentations and extensive follow-up dialogue and small-group discussion. Topics discussed in the course include research subject eligibility and recruitment, clinical trial design, data management and quality control, grant writing, and more!

Each participant will be expected to have a research project that can be developed in discussions with faculty and with peers.


The 2021 course directors are Christopher N. Bredeson, MD, MSc FRCPC FASTCT, The Ottawa Hospital/University of Ottawa and Margaret MacMillan, MD, MSc, FRCPC, University of Minnesota.

Faculty members will share their career stories and anecdotes. They will tell how they got where they are and the lessons learned along with way. Free time for rest, recreation and creative thinking will be built into the schedule.

Eligibility and Application

Applicants must be an ASTCT member who is currently either a fellow or junior faculty. The course defines junior faculty as an individual who has two years or less of experience in the blood and marrow transplantation and/or cellular therapy field. If you are not a member, click here to learn more about our free in-training membership.

Previous Clinical Research Training Course scholars are not eligible for the 2021 course. Unsuccessful applicants are encourage to apply for 2021. 

The applicant must identify a local mentor with whom to work in implementation of the research project after the course. The proposal should reflect what the applicant is planning to work on and not what they think the faculty would like.  

  • Applicant and mentor contact information 
  • Letter of recommendation from their mentor. Note: mentors must be an ASTCT member.
  • Curriculum vitae - a biosketch will not be accepted
  • A 2-5 page letter of application which includes the following information:
    1. The applicant’s background, training, interest in blood and marrow transplantation and clinical research and career goals
    2. An outline of a research project to be further developed during the course. Details of the proposed research project should be a major portion of the application letter and should at a minimum include the following headings:
      • Protocol Title
      • Background
      • Hypothesis and Aims
      • Study Design, Innovation
      • Potential problems/challenges, Summary.

Applications should be submitted in Arial, font size 11 with 1 inch margins. References should be included in the 2 - 5 page count. A separate page of references will not be accepted. 

Applicant selection will be based on curriculum vitae, proposed project, local mentor and all other things being equal, regional representation. Please note, that since scholars will be accepted based in a large part on the merit of the submitted project, it is not possible to change the overall project concept after submission (or after acceptance onto this Course).

Thank You to our Supporters

This activity is supported through educational grants from the following companies:

Jazz Pharmaceuticals  

Merck & Co., Inc.